Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure.

Despite similar clinical endpoints, heart failure resulting from dilated cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM) appears to develop through different remodeling and molecular pathways. Current understanding of heart failure has been facilitated by microarray technology. We constructed an in-house spotted cDNA microarray using 10,272 unique clones from various cardiovascular cDNA libraries sequenced and annotated in our laboratory. RNA samples were obtained from left ventricular tissues of precardiac transplantation DCM and HCM patients and were hybridized against normal adult heart reference RNA. After filtering, differentially expressed genes were determined using novel analyzing software. We demonstrated that normalization for cDNA microarray data is slide-dependent and nonlinear. The feasibility of this model was validated by quantitative real-time reverse transcription-PCR, and the accuracy rate depended on the fold change and statistical significance level. Our results showed that 192 genes were highly expressed in both DCM and HCM (e.g., atrial natriuretic peptide, CD59, decorin, elongation factor 2, and heat shock protein 90), and 51 genes were downregulated in both conditions (e.g., elastin, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase). We also identified several genes differentially expressed between DCM and HCM (e.g., alphaB-crystallin, antagonizer of myc transcriptional activity, beta-dystrobrevin, calsequestrin, lipocortin, and lumican). Microarray technology provides us with a genomic approach to explore the genetic markers and molecular mechanisms leading to heart failure.

[1]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[2]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[3]  P. Hurlin,et al.  The interplay between Mad and Myc in proliferation and differentiation. , 2001, Trends in cell biology.

[4]  A. Marian,et al.  Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. , 2001, Journal of the American College of Cardiology.

[5]  Thomas D. Wu,et al.  Analysing gene expression data from DNA microarrays to identify candidate genes , 2001, The Journal of pathology.

[6]  H. Izawa,et al.  Reduced Myocardial Sarcoplasmic Reticulum Ca2+-ATPase mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy , 2001, Circulation.

[7]  C. Seidman,et al.  Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. , 2001, American journal of human genetics.

[8]  Jason C. Mills,et al.  DNA microarrays and beyond: completing the journey from tissue to cell , 2001, Nature Cell Biology.

[9]  T. Hewett,et al.  Expression of R120G–αB-Crystallin Causes Aberrant Desmin and αB-Crystallin Aggregation and Cardiomyopathy in Mice , 2001 .

[10]  A. Marian.  On genetics of dilated cardiomyopathy and transgenic models: all is not crystal clear in myopathic hearts. , 2001, Circulation research.

[11]  A. Nairn,et al.  Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes. , 2001, American journal of physiology. Heart and circulatory physiology.

[12]  H. Lai,et al.  Developing a Strategy to Define the Effects of Insulin-Like Growth Factor-1 on Gene Expression Profile in Cardiomyocytes , 2001, Circulation research.

[13]  M. Oh,et al.  Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. , 2001, Nucleic acids research.

[14]  L. Fananapazir,et al.  Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. , 2001, The New England journal of medicine.

[15]  V. Dzau,et al.  Genomics and the pathophysiology of heart failure , 2001, Current cardiology reports.

[16]  E. Takashi,et al.  Expression and localization of lumican in the ischemic and reperfused rat heart. , 2001, Japanese circulation journal.

[17]  J. Towbin,et al.  Novel Gene Mutations in Patients With Left Ventricular Noncompaction or Barth Syndrome , 2001, Circulation.

[18]  C. Liew,et al.  Organization of human cardiovascular-expressed genes on chromosomes 21 and 22. , 2001, Journal of molecular and cellular cardiology.

[19]  J. Ko,et al.  Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model , 2001, FEBS letters.

[20]  D. Stamatiou,et al.  Construction of a human cardiovascular cDNA microarray: portrait of the failing heart. , 2001, Biochemical and biophysical research communications.

[21]  A. Galecki,et al.  Interpretation, design, and analysis of gene array expression experiments. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  L. Hawthorn,et al.  Decreased SLIM1 Expression and Increased Gelsolin Expression in Failing Human Hearts Measured by High-Density Oligonucleotide Arrays , 2000, Circulation.

[23]  A. Yuan,et al.  Quantification of VEGF mRNA Expression in Non-Small Cell Lung Cancer Using a Real-Time Quantitative Reverse Transcription-PCR Assay and a Comparison with Quantitative Competitive Reverse Transcription-PCR , 2000, Laboratory Investigation.

[24]  M. Perretti,et al.  Lipocortin 1 reduces myocardial ischemia‐reperfusion injury by affecting local leukocyte recruitment , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  L. Fananapazir,et al.  Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[26]  G. A. Whitmore,et al.  Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Rubin,et al.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Ton,et al.  A cardiovascular EST repertoire: progress and promise for understanding cardiovascular disease. , 2000, Molecular medicine today.

[29]  C. Lee,et al.  Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. , 2000, Genomics.

[30]  L. Stanton,et al.  Altered patterns of gene expression in response to myocardial infarction. , 2000, Circulation research.

[31]  Neil E. Bowles,et al.  The “Final Common Pathway” Hypothesis and Inherited Cardiovascular Disease The Role of Cytoskeletal Proteins in Dilated Cardiomyopathy , 2000, Herz.

[32]  T. Hewett,et al.  Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. , 2000, The Journal of clinical investigation.

[33]  L. Twiggs,et al.  Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. , 2000, Gynecologic oncology.

[34]  P. Trouvé,et al.  Expression and Localization of the Annexins II, V, and VI in Myocardium from Patients with End-Stage Heart Failure , 2000, Laboratory Investigation.

[35]  N. Steuerwald,et al.  Analysis of gene expression in single oocytes and embryos by real-time rapid cycle fluorescence monitored RT-PCR. , 1999, Molecular human reproduction.

[36]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[37]  D. Sawyer,et al.  Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. , 1999, Circulation research.

[38]  L. Fananapazir.  Advances in molecular genetics and management of hypertrophic cardiomyopathy. , 1999, JAMA.

[39]  S. Tyagi,et al.  Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. , 1999, Journal of hypertension.

[40]  G. Dorn,et al.  Cardiac-specific Overexpression of Mouse Cardiac Calsequestrin Is Associated with Depressed Cardiovascular Function and Hypertrophy in Transgenic Mice* , 1998, The Journal of Biological Chemistry.

[41]  H. Nishi,et al.  Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. , 1998, Circulation research.

[42]  M. Yacoub,et al.  Cardiac protein abnormalities in dilated cardiomyopathy detected by two‐dimensional polyacrylamide gel electrophoresis , 1998, Electrophoresis.

[43]  K P Fung,et al.  A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. , 1997, Circulation.

[44]  A. Belcastro,et al.  A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy , 1997, Molecular and Cellular Biochemistry.

[45]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[46]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[47]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[48]  L. Fananapazir,et al.  Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. , 1995, Circulation.

[49]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[50]  S. Izumo,et al.  Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene. , 1992, Circulation research.

[51]  曽村 富士.  Reduced myocardial sarcoplasmic reticulum Ca[2+]-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy , 2003 .

[52]  Andreas D. Baxevanis,et al.  The Molecular Biology Database Collection: 2002 update , 2002, Nucleic Acids Res..

[53]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[54]  K. Wirtz,et al.  Peptide-based targeting of fluorophores to peroxisomes in living cells. , 2001, Trends in cell biology.

[55]  A. Holmgren,et al.  Antioxidant function of thioredoxin and glutaredoxin systems. , 2000, Antioxidants & redox signaling.

[56]  T. Schwarz.  No eczema without keratinocyte death. , 2000, The Journal of clinical investigation.

[57]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[58]  H. Hirzel,et al.  Atrial and ventricular isomyosin composition in patients with different forms of cardiac hypertrophy. , 1987, Basic research in cardiology.